WO1991018001A1 - Trans-dominant suppressor genes for oligomeric proteins - Google Patents
Trans-dominant suppressor genes for oligomeric proteins Download PDFInfo
- Publication number
- WO1991018001A1 WO1991018001A1 PCT/US1991/003467 US9103467W WO9118001A1 WO 1991018001 A1 WO1991018001 A1 WO 1991018001A1 US 9103467 W US9103467 W US 9103467W WO 9118001 A1 WO9118001 A1 WO 9118001A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- trans
- subunit
- pdgf
- single stranded
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 48
- 108700025695 Suppressor Genes Proteins 0.000 title claims abstract description 36
- 235000018102 proteins Nutrition 0.000 claims abstract description 47
- 108020004414 DNA Proteins 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 22
- 102000053602 DNA Human genes 0.000 claims abstract description 20
- 108020004682 Single-Stranded DNA Proteins 0.000 claims abstract description 18
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 16
- 230000006337 proteolytic cleavage Effects 0.000 claims abstract description 16
- 238000013519 translation Methods 0.000 claims abstract description 11
- 230000003197 catalytic effect Effects 0.000 claims abstract description 9
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 8
- 230000007017 scission Effects 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 17
- 108020004705 Codon Proteins 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims 5
- 235000020776 essential amino acid Nutrition 0.000 claims 1
- 239000003797 essential amino acid Substances 0.000 claims 1
- 238000012545 processing Methods 0.000 abstract description 10
- 238000002741 site-directed mutagenesis Methods 0.000 abstract description 8
- 239000000178 monomer Substances 0.000 abstract description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 38
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 8
- 238000001890 transfection Methods 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 2
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000008747 mitogenic response Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- TRANS-DOMINANT SUPPRESSOR GENES FOR OLIGOMERIC PROTEINS The invention relates to trans-dominant suppressor genes.
- PDGF platelet derived growth factor
- a and B are expressed from separate genes and are active as either homo or heterodimers. Dimerization occurs through disulfide linkage between cysteine residues on the individual subunits. The positioning of these residues is conserved between the A and B chains, and between species at least as divergent as human and Xenopus.
- the initial translation product of the PDGF A and B genes is a "preproPDGF**.
- a hydrophobic leader seguence (the "pre” sequence) and a substantial length of N-terminal material (the “pro” sequence) are removed by proteolytic cleavage to generate the mature form of a
- the invention features two methods of making eucaryotic cell trans-dominant suppressor genes encoding a polypeptide translation product capable of suppressing the activity of a protein that requires an oligomeric state for function, the suppressor genes made by the methods, and the protein products of the respective suppressor genes.
- Each suppressor gene encodes a mutant subunit of the oligomeric protein that will suppress the wild type activity of the protein.
- the method includes isolating single stranded DNA encoding a subunit of the protein, the subunit being one that is initially synthesized containing extraneous peptide material which is subsequently removed by cleavage at a proteolytic cleavage site to generate the mature form of the subunit; modifying the base sequence in the single stranded DNA in the region encoding the proteolytic cleavage site, so that proteolytic cleavage of the initial translation product of the single stranded DNA to the mature form is prevented; and cloning the modified, single stranded DNA to form the trans-dominant suppressor gene.
- the modifying step includes addition or deletion of a codon for an amino acid essential for cleavage at the proteolytic cleavage site, or, preferably, substitution of one such essential codon by a codon for a different amino acid.
- the method includes isolating single stranded DNA encoding a subunit of the protein, the subunit being one that is bonded in the oligomeric state by means of a plurality of cysteine residues, at least one of which is essential for the catalytic activity of the protein; modifying in the DNA strand the if*- codon for one of the cysteine residues essential for the catalytic activity of the protein so that another amino 5 acid is substituted for the one cysteine residue, the codon for at least one cysteine residue remaining unmodified; and cloning the modified, single stranded DNA to form the trans-dominant suppressor gene.
- the oligomeric protein 10 is a growth factor, preferably PDGF, and the subunit is preferably PDGF A. In other preferred embodiments the protein is a transcription factor.
- the invention features a transgenic non-human animal that includes germ cells and 15 somatic cells including the trans-dominant suppressor gene introduced into the animal, or an ancestor of the animal, at an embryonic stage.
- the trans-dominant suppressor gene is under the control of a tissue specific promoter.
- the invention enables the systematic preparation, without undue experimentation, of a trans- dominant suppressor gene encoding a mutant subunit of an oligomeric protein that will suppress the wild type activity of the protein.
- Such suppressor genes can be 25 used to produce variant strains of transgenic laboratory or farm animals useful for observing the effects of tissue specific or systemic suppression of a particular wild type gene.
- the mutant product of the suppressor gene can be used in therapeutic applications.
- Fig. 1 is a representation of the murine 35 preproPDGF A chain and sites of directed mutagenesis.
- Fig. 2 is a representation of possible interactions between heterodimers of PDGF wild type and dominant suppressor subunits on the one hand, and PDGF receptor isoforms on the other hand. Description of the Preferred Embodiments
- the invention enables the preparation of trans-dominant suppressor genes encoding mutant subunits of two different categories of oligomeric proteins.
- the protein is composed of subunits at least one of which is initially synthesized containing extraneous peptide material. This extraneous material sequence is subsequently removed during normal processing by cleavage at a proteolytic cleavage site to generate the mature form of the subunit.
- single stranded DNA encoding the initial form of the indicated subunit is cloned, and the base sequence of the DNA in the region encoding the proteolytic cleavage site is modified by site directed mutagenesis so that processing of the translation product of the gene to the mature form of the subunit is prevented.
- the oligomeric protein is one in which the monomers are bonded together by at least two disulfide bonds, at least one of which is essential for the catalytic activity of the protein.
- single stranded DNA encoding one of the subunits is cloned, and the base sequence of the DNA in the region encoding a cysteine residue essential for catalytic activity is modified by site directed mutagenesis. The codon for at least one cysteine residue remains unmodified.
- the resulting translation product of the altered gene of either category will still bind to wildtype subunits; yet the resultant oligomers will be inactive.
- the protein product of the suppressor gene thus serves to suppress the wild type activity.
- mutant 1317 the modification involved was a change in the proteolytic cleavage site for processing the prepro form of the murine PDGF A chain to the mature form.
- the tetra basic amino acid sequence -ArgArgLysArg- (12) was selected as the target sequence for the protease that converts proPDGF A to PDGF A on the basis of observations that the amino terminus of mature PDGF A begins with the amino acid -Ser- (14) immediately to the carboxyl side of this tetra basic residue and that a string of three to five basic amino acids is found in a comparable position within the reading frames of other growth factors that undergo similar processing, notably PDGF B, TGF- ⁇ l, and TGF- ⁇ 2.
- Site directed mutagenesis was used to alter the sequence -ArgLysArg- (16) at this putative proteolytic cleavage site to - SerAsnGly- (18) . Changing the amino acid sequence in this drastic manner served to prevent removal of the propeptide.
- mutant 1308 the modification involved was a change in the codon for one of four essential cysteine residues in the PDGF A chain. Again referring to the Fig. 1, site directed mutagenesis was used to alter the codon TGC (20) for the third cysteine residue in the chain to AGC, to code for serine (22) . Characterization of products of mutant genes
- the two mutant cDNAs and the wild- type PDGF A cDNA were cloned into the pMT2 expression vector, and each of these constructs was transfected into COS cells.
- the COS cell cultures were incubated with 35S-cysteine to label the translation products, and the conditioned media were analyzed by immunoprecipitation with PDGF A chain-specific antibodies.
- the wild-type PDGF A cDNA produces a species that is consistent with previous determinations of the molecular weight of PDGF A (16 kd) .
- Co-transfection of COS cells with equal amounts of the wild-type and 1317 mutant constructs produces a major band at 38 kd on non-reducing gels, showing that a 1317/wild-type heterodimer is formed in which the wild-type protein is properly processed.
- Co-transfection of wild type with the 1308 construct did not result in any obvious structural changes. However, the abundance of the wild-type protein was decreased substantially.
- a series of transfections carried out with a fixed amount of the wild-type construct along with increasing amounts of the 1308 mutant showed that increasing amounts of the mutant resulted in a steady decrease in the amount of the wild-type protein expressed in the conditioned media. The mutant and the mutant/wild-type dimers appear to be subject to rapid degradation.
- the biological inactivity of the protein products of the mutant genes was demonstrated using a bioassay for PDGF.
- Transfection of 17.5 ⁇ g of either of the mutant constructs resulted in less than 1 ng/ml of activity. This level of expression is not significantly above the background level produced from COS cells transfected by the pMT2 expression vector alone.
- COS cells were co-transfected with 2.5 ⁇ g of the wild-type PDGF A chain construct along with increasing amounts of mutant constructs.
- Total DNA was adjusted to a constant 20 ⁇ g per transfection by addition of the pMT2 vector to minimize variations in transfection efficiency.
- Transfections with a 3- or 7-fold excess of 1317 DNA relative to wild-type DNA resulted in approximately 5- and 10-fold decreases in activity, respectively.
- Transfections with the wild- type gene and the 1308 mutant show a similar decrease in PDGF activity.
- the processing mutant, 1317 results in formation of a mutant/wild-type heterodimer that is efficiently secreted, but is biologically inactive, while the 1308 mutant appears to destablize the heterodimer, causing its degradation prior to release from the cells.
- the uses of dominant suppressor genes fall into two distinct categories. Within the first category, the genes themselves would be used to produce variant strains of transgenic laboratory or farm animals. Within the second category, the genes would be used to manufacture hetero oligomeric proteins containing a suppressor subunit in association with a wild type subunit. These hetero oligomeric proteins would function as competitive inhibitors of the natural protein; thus, they could have useful therapeutic applications. l. Example of using a dominant suppressor gene to create a transgenic laboratory animal which will serve as a disease model for medical research. The amino acid sequence of the two genes which encode PDGF (PDGF A and PDGF B) has been stringently preserved from humans down through lower vertebrates.
- the A gene of PDGF is expressed at extremely early times in the development of mammals and amphibians. For these reasons, it is believed that PDGF regulates important processes in normal physiology; however, the true functions of PDGF in vivo have not been established. Using dominant suppressor technology, a permanent strain of a mammal such as a laboratory mouse can be created which is unable to produce PDGF. Such a mouse can be used to study the functions of PDGF in vivo and to discover new drugs which might enhance or suppress those functions as needed.
- a PDGF dominant suppressor gene such as one of the PDGF A mutant cDNAs described above, can be placed downstream of a strong promoter which functions well in mice, such as the SV40 promoter, the cytomegalovirus promoter, or any of several retrovirus LTRs.
- a strong promoter which functions well in mice, such as the SV40 promoter, the cytomegalovirus promoter, or any of several retrovirus LTRs.
- Other usual features of a transgenic mouse vector splice donor/acceptor sites and a polyadenylation signal
- a permanent strain of transgenic mice which expresses the PDGF suppressor protein in virtually all tissues can be created.
- mutant protein would be of little or no consequence in tissues which do not manufacture PDGF.
- the dominant suppressor protein should inactivate the wild type PDGF A and/or B chains. (It has been found that the 1317 mutation will suppress wild type PDGF A activity while the 1308 mutation will suppress both wild type PDGF A and PDGF B activity.) If PDGF has essential functions at early times in vertebrate embryogenesis, tissue specific promoters such as platelet-factor 4 can be used which would only be expressed during adult life.
- PDGF A:B heterodi ers are not mitogenic; however, an excess of A:B heterodimer can inhibit the mitogenic response to a nominal dose of a B:B homodimer.
- the B subunit within A:B heterodimers is able to occupy 1/2 of a beta:beta receptor dimer without activating it and thereby render it useless for a productive interaction with PDGF B:B.
- Dominant suppressor genes can be used to manufacture useful therapeutic reagents that would have the same effect. Referring to Fig. 2, the proPDGF A subunit produced by mutant 1317 is too bulky to occupy the ⁇ receptor site.
- This subunit is able to dimerize with wild type PDGF (32) .
- This mutant heterodimer (32) should compete with either PDGF A:A or A:B, to inhibit the mitogenic response.
- a therapeutic reagent containing a proPDGF A:PDGF A heterodimer as described above can be administered by routine methods (e.g., intravenously) in pharmaceutically acceptable carrier substances, to a level of between 1-50 ng/ml (most preferably 1-10 ng/ml) final concentration.
- Dominant suppressor genes themselves, targeted into specific human or animal cells, can be used for therapeutic applications.
- Dominant suppressors which inhibit expression of PDGF can be another means of treating coronary artery disease, brain tumors, and other hyper-proliferative disorders of connective tissue such as rheumatoid arthritis.
- Other embodiments are within the following claims.
- murine trans-dominant PDGF A suppressors can be suppressors of murine PDGF B chain activity.
- the murine PDGF A dominant suppressors can also be used effectively in a wide range of species because the cysteines are highly conserved. This possibility has been confirmed by blocking the biological activity of the Xenopus laevis A chain using these mutants.
- the open-reading frame from pXOl a Xenopus A chain cDNA clone, is expressed in COS cells along with mutants 1317 and 1308, the mouse PDGF mutants are both effective at suppressing Xenopus PDGF.
- TGF- ⁇ transforming growth factor beta
- CSF-1 colony stimulating factor 1
- TGF- ⁇ 2 contains the following sequence at its processing site: -ArgArgLysLysArgAla- . This sequence was changed to -ArgGlnAsnGlnGlyAla- In both cases, the modification was effective in suppressing the corresponding growth factor.
- dominant suppressor genes can be prepared that will inhibit the activity of any oligomeric protein in which either, one subunit is initially synthesized containing a subsequently cleaved extraneous sequence (e.g., a "pro" sequence or an internal sequence) , or the monomers of the protein are bonded together by at least two disulfide bonds, at least one of which is essential for the catalytic activity of the protein.
- a subsequently cleaved extraneous sequence e.g., a "pro" sequence or an internal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP91510447A JPH05506361A (en) | 1990-05-17 | 1991-05-16 | Trans-dominant suppressor gene for multimeric proteins |
CA002083164A CA2083164A1 (en) | 1990-05-17 | 1991-05-16 | Trans-dominant suppressor genes for oligomeric proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52524590A | 1990-05-17 | 1990-05-17 | |
US525,245 | 1990-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991018001A1 true WO1991018001A1 (en) | 1991-11-28 |
Family
ID=24092499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/003467 WO1991018001A1 (en) | 1990-05-17 | 1991-05-16 | Trans-dominant suppressor genes for oligomeric proteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0528979A1 (en) |
JP (1) | JPH05506361A (en) |
CA (1) | CA2083164A1 (en) |
WO (1) | WO1991018001A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766073A (en) * | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521873B1 (en) * | 1990-01-29 | 1999-06-02 | Zymogenetics, Inc. | Anticoagulant proteins |
-
1991
- 1991-05-16 WO PCT/US1991/003467 patent/WO1991018001A1/en not_active Application Discontinuation
- 1991-05-16 EP EP91910731A patent/EP0528979A1/en not_active Withdrawn
- 1991-05-16 CA CA002083164A patent/CA2083164A1/en not_active Abandoned
- 1991-05-16 JP JP91510447A patent/JPH05506361A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766073A (en) * | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
Non-Patent Citations (6)
Title |
---|
ASUBEL et al. (eds.), "Current Protocols in Molecular Biology", published 1988 by John Wiley & Sons (N.Y.), pages 8.0.1-8.1.4, see entire document. * |
HAMES et al. (eds.), "Transcription and Splicing", published 1988 by IRL Press (Oxford, GB), pages 1-41, see entire document. * |
L. STRYER, "Biochemistry", published 1975 by W.H. Freeman and Co. (CA), page 503, see entire document. * |
Molec. Cell. Biol., Vol. 8, issued March 1988, SAUER et al., "Identification of Nonessential Disulfide Bonds and Altered Conformations in the v-sis Protein, a Homolog of the B Chain of Platlet-Derived Growth Factor", pages 1001-1018. * |
Nature, Vol. 329, issued 17 September 1987, I. HERSKOWITZ, "Functional inactivation of genes by dominant negative mutations", pages 219-222, see entire document. * |
See also references of EP0528979A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0528979A4 (en) | 1994-02-16 |
JPH05506361A (en) | 1993-09-22 |
CA2083164A1 (en) | 1991-11-18 |
EP0528979A1 (en) | 1993-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee | Expression of growth/differentiation factor 1 in the nervous system: conservation of a bicistronic structure. | |
Tashiro et al. | Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. | |
Lyons et al. | Vgr-1, a mammalian gene related to Xenopus Vg-1, is a member of the transforming growth factor beta gene superfamily. | |
US7709270B2 (en) | Vascular endothelial growth factor C (VEGF-C) protein diagnostic | |
Levelt et al. | Restoration of early thymocyte differentiation in T-cell receptor beta-chain-deficient mutant mice by transmembrane signaling through CD3 epsilon. | |
Bok et al. | Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation | |
JP4524340B2 (en) | Vascular endothelial growth factor C (VEGF-C) protein and its genes, variants, and uses thereof | |
JPH06504185A (en) | Ligands for C.KIT receptors and their use | |
Schwall et al. | Recombinant expression and characterization of human activin A | |
US20190376083A1 (en) | Synp1, a promoter for the specific expression of genes in interneurons | |
KR20180084136A (en) | A promoter for the specific expression of genes in the light photoreceptor SynP161 | |
Charlab et al. | The salivary adenosine deaminase from the sand fly Lutzomyia longipalpis | |
EP3548093A1 (en) | Synp107, a promoter for the specific expression of genes in interneurons | |
JP2749838B2 (en) | Interleukin-7 | |
DE69434519T2 (en) | PROHORMONE CONVERTASE EXPRESSIVE POLYPEPTIDE SYNTHESIS | |
RU2180850C2 (en) | Pharmaceutical composition containing c-kit-ligand and hemopoietic factor, method of enhancement of peripheral blood stem cell levels, antagonist of c-kit-ligand, antisense molecule of nucleic acid, method of enhancement of peripheral blood cell levels ex-vivo | |
HU218411B (en) | Megakaryocyte differentiation factor | |
CA2398660A1 (en) | Human cyr61 | |
US6475781B1 (en) | Trans-dominant suppressor genes for oligomeric proteins | |
CA2102129C (en) | Growth hormone antagonists | |
Hallböök et al. | Production and characterization of biologically active recombinant beta nerve growth factor | |
WO1993009234A2 (en) | Suppressor and progenitor cells | |
WO1991018001A1 (en) | Trans-dominant suppressor genes for oligomeric proteins | |
Tavernor et al. | Expression cloning of an equine T‐lymphocyte glycoprotein CD2 cDNA: Structure‐based analysis of conserved sequence elements | |
AU593118B2 (en) | Polypeptide competitor for immunoglobulin e |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991910731 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2083164 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991910731 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991910731 Country of ref document: EP |